Please try another search
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.
Name | Age | Since | Title |
---|---|---|---|
Donald D. Cilla | - | 2020 | CEO, President & Director |
Armand Balboni | 56 | 2019 | Chairman of the Board |
Theresa Matkovits | 56 | 2018 | Lead Independent Director |
Sridhar Narayan | - | - | Member of Scientific Advisory Board |
Lidija Marusic | - | 2019 | Board Observer |
Brian Matthew Bloom | 46 | 2015 | Director |
Lynn L. Silver | - | - | Member of Advisory Board |
Juergen Froehlich | 67 | 2020 | Independent Director |
Dean L. Shinabarger | - | - | Member of Advisory Board |
Prakash Gowd | 59 | 2023 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review